News Daily News Novel Aldosterone Synthase Inhibitor Drops BP: Top-line Phase II Results Todd Neale November 16, 2022
News Conference News AHA 2022 Endothelin Receptor Antagonist Effective in Resistant Hypertension: PRECISION Michael O'Riordan November 09, 2022
News Conference News AHA 2022 SPYRAL HTN-ON MED Trial of Renal Denervation Misses Primary Endpoint Todd Neale November 09, 2022
News Conference News AHA 2022 Big Drops in Blood Pressure With Baxdrostat: BrigHTN Phase II Study Michael O'Riordan November 07, 2022
News Conference News TCT 2022 SYMPLICITY HTN-3’s Late Surprise: Sustained BP Drop at 3 Years Despite Earlier Miss Michael O'Riordan September 19, 2022
Presentation TCT 2022 TCT 212: Twenty-Four Month Results in Patients with Resistant Hypertension After Endovascular Ultrasound Renal Denervation in the RADIANCE-HTN TRIO Trial Presenter: Roland Schmieder September 17, 2022
News Conference News ESC 2022 TIME of Antihypertensive Dose Doesn’t Matter for CV Protection Todd Neale August 26, 2022
News Daily News RADIANCE II Top-Line Results Promising for Ultrasound Renal Denervation Todd Neale July 26, 2022
News Conference News EuroPCR 2022 Registry Data Hint at MACE Benefit With Renal Denervation Michael O'Riordan May 17, 2022